
Australian investors are being reminded by treasurer Jim Chalmers that global turmoil is pressuring budgets and inflation, even as the country tries to avoid recession. Periods like this often reward businesses that can grow earnings from their own steam rather than relying on a booming economy. That is exactly what this group of high potential Australian growth stocks targets. This article highlights three of the strongest candidates from that list.
The three stocks below are just a small sample of this theme. The full screen surfaces 90 more Australian businesses with similarly compelling growth stories that are not covered in this article. To sift through that broader universe and identify candidates that fit your own risk and return preferences, jump into the Healthy high growth potential screener.
Overview: Starpharma Holdings is a biopharmaceutical company developing dendrimer based drug delivery platforms and healthcare products, including DEP oncology candidates.
Operations: Starpharma generates about A$12.7 million in revenue from the discovery, development and commercialization of dendrimer based products.
Market Cap: A$381.5 million
Starpharma Holdings fits the Healthy high growth potential theme through its DEP oncology platform, with earnings forecast to grow rapidly and profitability expected within three years. Index inclusions and fresh equity funding add visibility and runway. What matters most now is how one unresolved clinical and commercial hurdle shapes that ambitious earnings path.
That hinge point is exactly what the analysis report for Starpharma Holdings unpacks, so you can see how the clinical path could reshape Starpharma Holdings' earnings profile.
Overview: Wisr is an Australian consumer lender offering a wide range of unsecured and secured personal loans, supported by its digital Wisr app.
Operations: Wisr generates A$28.1 million in revenue from providing personal loans to consumers in Australia, its sole reported market.
Market Cap: A$54.6 million
Wisr connects directly with the Healthy high growth potential theme through its consumer lending platform. The loan book and digital origination engine influence how quickly earnings can scale from here.
"Proprietary technology and automation provide Wisr with a scalable cost advantage, supporting rapid expansion and improved margins versus competitors."
An important consideration is what happens to Wisr’s valuation story if funding structure pressures tighten at the same time that growth ambitions require additional balance sheet capacity.
If that funding tension is what you are watching, read the full narrative for Wisr to see how Wisr’s growth engine could accelerate or stall from here.
Overview: SKS Technologies Group designs, supplies, and installs advanced audiovisual, electrical, and communications systems across Australian commercial, education, and public infrastructure projects.
Operations: SKS Technologies Group generates about A$347.9 million in sales from lighting and audio visual markets within Australia.
Market Cap: A$1.26 billion
SKS Technologies Group is relevant for the Healthy high growth potential theme because its high-spec AV integration and support contracts can compound earnings as clients upgrade digital infrastructure across offices, campuses, and data heavy facilities.
"The rapid acceleration of digital transformation and surging demand for data centers is associated with significant growth in SKS Technologies' project pipeline, including a 92% increase in revenue and a 46% rise in tender activity year-on-year."
What could really shift the story now is how one pressure around funding those larger, higher margin projects ultimately shapes future profitability.
If that funding risk is what you are weighing, read the full narrative for SKS Technologies Group to see whether SKS Technologies Group’s accelerating project mix could actually strengthen long term economics.
Fresh ideas move first. Once momentum builds, prices can break out fast and early data starts dropping out of view. Scan these under the radar picks while it matters and act now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com